AIP
SRNE

Ahrens Investment Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Ahrens Investment Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,000
Closed -$2K – 995
2022
Q2 		$2K Hold
1,000
– – ﹤0.01% 900
2022
Q1 		$2K Hold
1,000
– – ﹤0.01% 972
2021
Q4 		$5K Buy
+1,000
New +$6.21K ﹤0.01% 893

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ahrens Investment Partners's SRNE Position: Q3 2022 in Review

Ahrens Investment Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2022, closing a stake of 1,000 shares — an estimated $2K sold.

Ahrens Investment Partners first reported a position in SRNE in Q4 2021 and held it in 3 quarters. The position peaked at $5K in Q4 2021. 233 funds tracked by Wall St. Rank hold SRNE as of Q3 2022.

  • Ahrens Investment Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Ahrens Investment Partners sold 1,000 Sorrento Therapeutics, Inc. shares in Q3 2022, an estimated $2K.
  • Ahrens Investment Partners first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 3 quarters.
  • Ahrens Investment Partners's Sorrento Therapeutics, Inc. position peaked at $5K in Q4 2021.
  • 233 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2022.

Based on Ahrens Investment Partners's 13F filing for Q3 2022, filed 8 Nov 2022.